Background. Interstitial fibrosis and tubular atrophy (IFTA) associated with interstitial inflammation in nonscarred areas (IFTA+i) is associated with poorer graft outcome than inflammation without IFTA or IFTA without inflammation. Methods. We evaluated if histological categories at week 6 could predict the development of interstitial fibrosis and de novo donor specific anti-HLA antibodies (dnDSA) at 1 year. Biopsies were classified according to Banff criteria as normal (i+t≤1 and ci+ct≤1), inflammation (i+t≥2 and ci +ct≤1), IFTA (i+t≤1 and ci+ct≥2) or IFTA+i (i+t≥2 and ci+ct≥2). Results. We analyzed 598 standard immunological risk recipients. The histological diagnosis at 6 weeks was: normal (n = 206), inflammation (n = 29), IFTA (n = 255), and IFTA+i (n = 108). Moderate/severe interstitial fibrosis (ci≥2) at 1 year was observed in 4.2% of patients with prior (6 weeks) normal histology, in 3.4% with inflammation, in 13.8% with IFTA, and in 24.5% with IFTA+i (P = 0.0001). Fifty-three recipients (8.9%) had dnDSA at 1 year. Independent predictors of development of dnDSA at 1 year were: HLA-DR mismatches (odds ratio [OR], 1.95; 95% confidence interval [95% CI], 1.09-3.49), the presence of inflammation (OR, 5.49; 95% CI, or IFTA+i (OR, 4.09; 95% CI, 1.67-10.0) in the 6-week surveillance biopsy. Conclusions. Early subclinical inflammation in surveillance biopsies with or without tubulointerstitial chronic lesions is associated with an increased risk of dnDSA development.
T he presence of tubulointerstitial inflammation in early surveillance renal allograft biopsies has been associated with progression of interstitial fibrosis 1 and decreased renal allograft survival. 2 However, in these studies, the presence or absence of interstitial fibrosis and tubular atrophy (IFTA) was not taken into consideration for the evaluation of subclinical inflammation. In later studies, it was observed that renal allograft survival was significantly shortened if surveillance biopsies showed IFTAwith interstitial inflammation in nonscarred areas (IFTA+i), whereas inflammation not associated with IFTA was a relatively uncommon finding and was associated with graft survival comparable to normal biopsies and biopsies with IFTA without inflammation. [3] [4] [5] The reason why IFTA+i is associated with a poor outcome has not been clarified.
The presence of inflammation in early surveillance biopsies has been associated with an enhanced donor specific memory T cell response, 6 suggesting that subclinical inflammation may represent a surrogate of the alloimmune response. Recently, this notion has been reinforced by the description of a temporal association between early subclinical inflammation and an increased risk for de novo donor-specific anti-HLA antibodies (dnDSA), as well as antibody-mediated rejection (AMR). 7, 8 It is not known whether inflammation in otherwise normal biopsies and in biopsies with IFTA+i imply a different risk for development of dnDSA. Additionally, it is not clear whether the presence of microvascular injury in early surveillance biopsies also contributes to an increased risk of dnDSA. 8 The aim is to evaluate if the presence of IFTA+i in 6 weeks surveillance biopsies implies a differential risk for the progression of fibrosis and development of dnDSA at 1 year than the presence of inflammation not associated with IFTA.
MATERIALS AND METHODS

Patients
All patients with a negative cytotoxic T cell and B cell crossmatch, panel-reactive antibody (PRA) of 20% or less and donor-specific antibodies (DSA) negative before transplantation, receiving a single kidney transplant at Oslo University Hospital Rikshospitalet between January 2009 and December 2012 were considered. Patients were followed up during the first year after transplantation. At our tissuetyping laboratory, a PRA of 20% or less is considered as low immunological risk. Only patients receiving a calcineurinbased immunosuppressive regimen with a surveillance biopsy at 6 ± 2 weeks and 1 year (±2 month) and an anti-HLA antibody determination at the time of both biopsies were included in the present analysis. Patients receiving a kidney from a HLA-identical donor or ABO-incompatible graft were excluded. The study was approved by the SouthEastern Regional Committee for Medical and Health Research Ethics in Norway and was performed in accordance with the Declaration of Helsinki and is consistent with the Principles of the Declaration of Istanbul on Organ Trafficking and Transplant Tourism. All patients gave their written informed consent.
Biopsies
Two cores were obtained with ultrasound guidance using an 18-gauge spring-loaded biopsy gun, 1 for histology (hematoxylin-eosin and saffron, periodic acid-Schiff and Masson trichrome) and 1 for C4d. Both biopsies contained at least 1 glomerular and 1 arterial profile and sufficient tubulointerstitial tissue to grade interstitial inflammation (i), tubulitis (t), interstitial fibrosis (ci), and tubular atrophy (ct). C4d was stained with indirect immunofluorescence on frozen sections (monoclonal antibody; Quidel, San Diego, CA). Grade 3 diffuse C4d staining in more than 50% of peritubular capillaries was classified as positive.
Histological Classification
Renal lesions were graded according to the Banff criteria. 9, 10 Biopsies were classified into 4 groups: (a) normal histology (i+t≤1 and ci+ct≤1), (b) inflammation (i+t≥2 and ci+ct≤1), (c) IFTA (i+t≤1 and ci+ct≥2), and (d) IFTA+i (i+t≥2 and ci +ct≥2). Areas with fibrotic scars were excluded from evaluation.
Anti-HLA Antibodies
Immunomagnetic cytotoxic T cell and B cell crossmatches were done at transplantation in all recipients. Additional testing on the Luminex platform LX200, using the LSM12-screening kit (1 Lambda) for identification of HLA class I and class II was performed. IgG antibody specificities was examined using single antigen-coated flow beads provided by 1 Lambda at transplantation and at the time of the 6-week and 1-year surveillance biopsies. We used a mean fluorescence intensity of 1000 as a cutoff value. As a negative control, we used serum (LS-NC) delivered by the kit producer (1 Lambda). No patient had DSA or PRA greater than 20% before or at transplantation.
Clinical Variables
All patients received induction therapy with basiliximab followed by a calcineurin inhibitor-based regimen (either cyclosporine [CsA] or tacrolimus [TAC]) in combination with mycophenolate and prednisone as previously described.
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Cyclosporine-based immunosuppression was used in recipients older than 50 years and in younger patients with impaired glucose tolerance test before transplantation as a strategy to limit the impact on posttransplant diabetes mellitus. Acute cellular rejections were treated with intravenous methylprednisolone, total dosage of 1375 mg, divided into 5 infusions. The oral prednisolone dose was increased to 30 mg/day and tapered 5 mg every other week. In case of steroid resistant rejection, rabbit antithymocyte globulin was administered. Acute AMR was additionally treated with plasmapheresis and/or intravenous immunoglobulin. Routinely, 5 plasmapheresis sessions were performed with replacement preferentially 4% albumin in Ringer (50 mL/kg bodyweight). In therapy resistant cases rituximab or rabbit antithymocyte globulin was administered. Delayed graft function was defined as the need of at least 1 dialysis session during the first 7 days after transplantation.
Statistical Analysis
Results are expressed as frequencies for categorical variables or as the mean ± standard deviation for continuous variables. Kruskal-Wallis, χ 2 , and analysis of variance were used to compare categorical, ordinal, or no-normally distributed continuous variables, and continuous normally distributed variables, respectively. All P values were 2-tailed, and a P value less than 0.05 was considered significant. Binomial and multinomial logistic regression analyses were carried out to study independent predictors of outcome variables. Variables with a P value less than 0.05 in the univariate analysis were included in the multivariate analysis.
RESULTS
During the study period, 1156 kidney transplants were performed. A total of 598 patients with a 6-week and 1-year biopsy with sufficient tissue for evaluation and with determination of dnDSA at the time of early and late biopsies were included. Reasons for exclusion are summarized in Figure 1 . Of note, 242 patients were excluded because 6-week biopsy or 1-year biopsy was not performed due to graft loss before 6 weeks (n = 9), graft loss between 6 weeks and 1 year (n = 6), patient death before 6 weeks (n = 1), patient death between 6 weeks and 1 year (n = 25), medical contraindication (n = 24), declined consent (n = 16), early transfer to the local hospital responsible for long-term follow-up (n = 105), and loss of follow-up (n = 56).
Reasons for graft failure during the first year were primary vascular problems (n = 6), acute rejection (n = 4), never functioning graft (n = 2), recurrence of primary kidney disease (n = 1), and not clarified reason (n = 2).
Causes of death during the first year were septicemia (n = 8), malignancies (n = 6), myocardial infarction (n = 2), cerebrovascular accident (n = 2), pneumonia (n = 2), mesenteric infarction (n = 1), cardiac arrest (n = 1), liver failure (n = 1), accident (n = 1), suicide (n = 1), and unknown reason (n = 1).
Histological Diagnosis at 6 Weeks
A total of 598 surveillance biopsies obtained 6 weeks after transplantation were evaluated. Of those, 567 were representative according to Banff criteria showing at least 7 glomeruli and 1 artery and 31 biopsies were under the threshold of adequacy showing between 1 and 6 glomeruli. Histological diagnoses were: normal (206), inflammation (29), IFTA (255), and IFTA+i (108). Thus, 12.3% (29 of 235) of patients had inflammation in biopsies without IFTA, whereas 29.8% (108 of 363) of patients had inflammation in biopsies already displaying IFTA (P < 0.0001).
Clinical Variables Associated With Histological Diagnosis at 6 Weeks
Characteristics of patients according to histological diagnosis at 6 weeks are summarized in Table 1 . For multinomial logistic regression, the reference category was normal histology. The number of HLA-DR mm (odds ratio [OR], 2.59; 95% . Serum creatinine at 6 weeks and at 1 year according to histological diagnosis at the time of the early surveillance biopsy is summarized in Figure 2 .
Evolution of Histological Lesions Between 6 Weeks and 1 Year
From 6 weeks to 1 year after transplantation, Banff scores for interstitial inflammation (0.34 ± 0.70 vs 0.32 ± 0.69) and tubulitis (0.48 ± 0.78 vs 0.46 ± 0.75) were not significantly changed. Banff scores for interstitial fibrosis showed however a significant increase from 0.67 ± 0.59 to 0.85 ± 0.72 (P < 0.0001) and tubular atrophy from 0.80 ± 0.56 to 0.99 ± 0.66 (P < 0.0001).
Seventy-two of 598 patients (12.04%) had a ci score of 2 or greater at 1 year. In Figure 3 , the relationship between histological diagnosis at 6 weeks and ci score of 2 or greater at 1 year is shown. In Table 2 , clinical data and histological diagnosis at 6 weeks according to the presence of a ci score of 2 or greater at 1 year are summarized. Logistic regression analysis showed that donor age (OR, 1.04; 95% CI, 1.01-1.07), the presence of an episode of acute rejection before the 6-week biopsy (OR, 2.48; 95% CI, 1.18-5.20), the presence of an episode of acute rejection between 6-week and 1-year biopsy (OR, 2.38; 95% CI, 1.08-5.30), and the presence of IFTA+i in the 6 week biopsy (OR, 4.21; 95% CI, 1.80-9.90) were independent predictors of a ci score of 2 or greater at 1 year.
Predictors of dnDSA at 1 Year
Fifty-three of 598 patients (8.9%) had dnDSA at 1 year. In Table 3 , clinical data and histological diagnosis at 6 weeks according to the presence of dnDSA at 1 year are summarized. Logistic regression analysis including clinical and histologic data at 6 weeks showed that the number of HLA-DR mm (OR, 1.95; 95% CI, 1.09-3.49), inflammation in 6-week biopsy (OR, 5.49; 95% CI, 1.67-18.03) and IFTA +i at 6 weeks (OR, 4.09; 95% CI, 1.67-10.05) were independent predictors of dnDSA at 1 year. The analysis was repeated excluding the 12 patients with dnDSA at 6 weeks, and the results were not modified (data not shown).
Microcirculatory Injury, C4d Deposition and dnDSA
There was no association between microcirculatory injury at 6 weeks and dnDSA at 1 year but peritubular capillaritis FIGURE 2. Serum creatinine according to histological diagnosis at 6 weeks and 1 year. and C4d deposition at 1 year were more common in patients displaying dnDSA (Table 4) .
DISCUSSION
The main finding of this surveillance biopsy analysis was that tubulointerstitial inflammation in biopsies without IFTA and in biopsies displaying IFTA+i at 6 weeks was associated with an increased prevalence of dnDSA at 1 year. Of note, the OR for dnDSA was similar in patients with inflammation and IFTA+i. On the contrary, microcirculatory injury at 6 weeks was not associated with an increased prevalence of dnDSA at 1 year, whereas the presence of dnDSA at 1 year was associated with microcirculatory injury at the same time.
Currently, AMR is regarded as a main cause of renal allograft failure 12 and the presence of DSA as an underlying necessity for its appearance. 13 Our understanding of AMR has evolved in the last decade. Acute AMR was initially included in the 2003 Banff classification, 14 chronic AMR in Banff 2005, 15 and subclinical AMR 10,16 was described few years later. Antibody-mediated rejection in patients with preformed DSA and dnDSA constitutes an evolving process that is manifested by different clinical phenotypes. 17 In the present study, we confirm that there is a temporal association between early subclinical tubulointerstitial inflammation and an increased risk for development of dnDSA. 7, 8, 18, 19 Altogether, these observations suggest that tubulointerstitial inflammation may constitute a trigger of the complex process leading to dnDSA synthesis. In our study, microcirculatory injury at 6 weeks was not associated with presence of dnDSA 1 year after transplantation, whereas 1-year dnDSA was associated with the presence of microcirculatory injury in 1-year biopsies. Consequently, our data may indicate that microcirculatory injury is not a trigger but a consequence of dnDSA.
The risk of dnDSA at 1 year was similar in patients with inflammation and IFTA+i, suggesting that inflammation constitutes a risk factor for dnDSA regardless of the presence or absence of fibrosis. This observation, as far as we know, has not been made before. In previous studies, it has been described that IFTA+i, but not inflammation in the absence of IFTA, is associated with decreased graft survival. 4 On the other hand, studies evaluating the relationship between early inflammation and the risk of dnDSA did not clarify whether the presence or absence of fibrosis in patients with inflammation modulates the risk of dnDSA. Thus, even mild inflammation in biopsies without fibrosis cannot be considered a nonsignificant lesion.
Risk factors associated with inflammation in biopsies without IFTA were the number of HLA-DR mm and the use of CsA in comparison to TAC, which can be considered surrogates of the alloimmune response. Donor age and male sex, representing surrogates of the quality of the kidney, and also HLA-B mm, were associated with IFTA. Finally, IFTA+i was associated with both: surrogates of the alloimmune response, that is, use of CsA, HLA-DR and HLA-B mm, as well as surrogates of the quality of the kidney such as donor age and male sex. Of note, the number of HLA-B mm can be considered a surrogate of the alloimmune response and was associated with IFTA. This association suggests that apart from preexisting donor-related chronic damage, alloimmune response might contribute to interstitial fibrosis in the absence of significant inflammation. This idea is in agreement with the observation that inflammation-related genes are upregulated in patients with chronic injury. 20, 21 The prevalence and intensity of inflammation is lower in TAC-treated patients than CsA-treated patients, a result that was confirmed in the present study. [22] [23] [24] [25] However, it is not known whether the use of immunosuppressive regimens associated with a low prevalence of subclinical inflammation is also associated with a decreased risk of dnDSA. In the present study, the probability to develop dnDSA was similar in patients treated with CsA and TAC. Nevertheless, in some clinical trials, it has been described that the risk of dnDSA is associated with the immunosuppressive schedule. 26, 27 Unfortunately, in these trials, surveillance biopsies were not done. Thus, the question whether prevention of early inflammation constitutes a strategy to prevent dnDSA deserves further study. The presence of IFTA+i, but not inflammation without IFTA at 6 weeks, was an independent predictor of the presence of moderate to severe interstitial fibrosis (ci score ≥ 2) at 1 year. Other independent predictors of the presence of ci score of 2 or greater at 1 year were donor age, the presence of a clinical episode of acute rejection before the 6 weeks surveillance biopsy, and the presence of an episode of acute rejection between the 2 surveillance biopsies. Altogether, these data not only suggest that clinical episodes of acute rejection constitute a driving force for the progression of fibrosis but also point out that in patients with fibrosis, superimposed inflammation accelerates the progression of fibrosis during the first year.
Our study has limitations. The most important one is the short follow-up of patients not allowing us to evaluate the relationship between inflammation, progression of interstitial fibrosis, dnDSA, and graft survival. Moreover, the relationship between type of treatment and inflammation or dnDSA cannot be properly analyzed since CsA was subscribed to patients at increased risk for posttransplant diabetes mellitus.
In summary, early subclinical inflammation in biopsies with or without tubulointerstitial chronic lesions, together with HLA DR mm, are associated with an increased risk of development of dnDSA 1 year after transplantation. In patients with IFTA+i in early biopsies, there is an increased risk for the progression of fibrosis at 1 year. Because type of immunosuppressive treatment modulates the severity of subclinical inflammation, it will be worth to explore whether treatment regimens associated with low prevalence of subclinical inflammation may in turn prevent the appearance of dnDSA.
